AnalystBook Research · Company Intelligence

ARDELYX, INC.

ARDXNasdaq

Built from ARDELYX, INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Ardelyx revenue rose 22.1% to $407.3M, but the net loss widened and debt rose.

The read at a glance✓ Audited against SEC data
  • Business mix — Commercial-stage biopharmaNote
  • Revenue — Revenue rose 22.1% to $407.3MOK
  • Profitability — Net loss widened to $61.6MWatch
  • Cash — FCF improved but stayed negativeNote
  • Balance sheet — Debt up; equity downWatch
  • Insiders — 1 buy / 25 sellsNote
  • Accounting — Altman-Z distress; EQ greyWatch

Business

Ardelyx is a commercial-stage biopharmaceutical company marketing IBSRELA and XPHOZAH, both based on tenapanor.

Where the revenue comes from

Fiscal 2025, as ARDELYX, INC. reports it. History and quarterly detail are in the app.

  • Product sales, net$377.8M
  • Other cost of revenue$29.5M
  • Product supply revenue$15.9M
  • Non-cash royalty revenue related to the sale of future royalties$8.5M
  • Licensing revenue$5.1M

Leadership changes

From ARDELYX, INC.'s own filings, the day they're filed.

  • Elizabeth Grammer · Directors · departureeff. 2025-12-31
  • Sue Hohenleitner · chief financial officer · appointmenteff. 2025-11-04
  • Onaiza Cadoret-Manier · directors · appointmenteff. 2025-06-18

Latest filings

  • 8-K · Company announcement2026-08-17
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-07-02
  • 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ARDELYX, INC., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full ARDX record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.